​

Atossa Therapeutics (ATOS) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChartTranscripts

ATOS Stock Forecast

Atossa Therapeutics (ATOS) stock forecast, based on 5 Wall Street analysts, predicts a 12-month average price target of $5.00, with a high of $5.00 and a low of $5.00. This represents a 481.40% increase from the last price of $0.86.

- $1 $2 $3 $4 $5 High: $5 Avg: $5 Low: $5 Last Closed Price: $0.86

ATOS Stock Rating

Atossa Therapeutics stock's rating consensus is Buy, based on 5 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 4 Buy (80.00%), 1 Hold (20.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 5 0 1 4 Strong Sell Sell Hold Buy Strong Buy

ATOS Price Target Upside V Benchmarks

TypeNameUpside
StockAtossa Therapeutics481.40%
SectorHealthcare Stocks 23.68%
IndustryBiotech Stocks 64.77%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.86$0.86$0.86
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 2521---3
May, 2521---3
Apr, 2521---3
Mar, 2521---3
Feb, 2521---3
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 08, 2023Louise ChenCantor Fitzgerald$5.00$0.83502.41%481.40%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 11, 2024AscendiantBuyBuyhold
Jul 01, 2024H.C. WainwrightBuyBuyhold
May 13, 2024H.C. WainwrightBuyBuyhold
Sep 08, 2023Cantor FitzgeraldOverweightinitialise

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.24-----
Avg Forecast$-0.24$-0.22$-0.27$-0.31$0.21$0.52
High Forecast$-0.22$-0.21$-0.25$-0.29$0.68$0.52
Low Forecast$-0.25$-0.22$-0.29$-0.32$-0.27$0.52
Surprise %------

Revenue Forecast

$50M $68M $86M $104M $122M $140M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$54.46M$82.35M$138.34M
High Forecast---$54.46M$82.35M$138.34M
Low Forecast---$54.46M$82.35M$138.34M
Surprise %------

Net Income Forecast

$-50M $-20M $10M $40M $70M $100M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-30.09M-----
Avg Forecast$-30.09M$-26.91M$-33.96M$-38.45M$8.02M$64.93M
High Forecast$-27.51M$-26.08M$-31.13M$-36.56M$85.74M$64.93M
Low Forecast$-31.63M$-27.32M$-36.11M$-40.35M$-34.04M$64.93M
Surprise %------

ATOS Forecast FAQ

Is Atossa Therapeutics stock a buy?

Atossa Therapeutics stock has a consensus rating of Buy, based on 5 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 4 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Atossa Therapeutics is a favorable investment for most analysts.

What is Atossa Therapeutics's price target?

Atossa Therapeutics's price target, set by 5 Wall Street analysts, averages $5 over the next 12 months. The price target range spans from $5 at the low end to $5 at the high end, suggesting a potential 481.40% change from the previous closing price of $0.86.

How does Atossa Therapeutics stock forecast compare to its benchmarks?

Atossa Therapeutics's stock forecast shows a 481.40% upside, outperforming the average forecast for the healthcare stocks sector (23.68%) and outperforming the biotech stocks industry (64.77%).

What is the breakdown of analyst ratings for Atossa Therapeutics over the past three months?

  • June 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2025: 66.67% Strong Buy, 33.33% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Atossa Therapeutics’s EPS forecast?

Atossa Therapeutics's average annual EPS forecast for its fiscal year ending in December 2024 is $-0.22, marking a -8.33% decrease from the reported $-0.24 in 2023. Estimates for the following years are $-0.27 in 2025, $-0.31 in 2026, $0.21 in 2027, and $0.52 in 2028.

What is Atossa Therapeutics’s revenue forecast?

Atossa Therapeutics's average annual revenue forecast for its fiscal year ending in December 2024 is $0, reflecting a 0% decrease from the reported $0 in 2023. The forecast for 2025 is $0, followed by $54.46M for 2026, $82.35M for 2027, and $138.34M for 2028.

What is Atossa Therapeutics’s net income forecast?

Atossa Therapeutics's net income forecast for the fiscal year ending in December 2024 stands at $-26.911M, representing a -10.58% decrease from the reported $-30.094M in 2023. Projections indicate $-33.964M in 2025, $-38.455M in 2026, $8.02M in 2027, and $64.93M in 2028.